Inhibrx Biosciences Inc.
Organization details
- Legal name
- Inhibrx Biosciences Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- La Jolla
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- INBX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002007919
- EIN
- 99-0613523
Board of directors
-
Douglas Forsyth · DirectorSince 2024
-
Jon Faiz Kayyem · DirectorSince 2024
-
Kimberly Manhard · DirectorSince 2024
-
Kristiina Vuori M.D. · DirectorSince 2024
-
Mark Lappe · Director · Chief Executive OfficerSince 2024
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-15% a year in revenue
20% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.9%
-
99.6%
Board connections
3 of this board's directors also sit on 3 other boards. 2 are in the same sector.
-
Biodesix Inc. Same sectorvia Jon Faiz Kayyem
- via Kristiina Vuori M.D.
-
Heron Therapeutics Inc. Same sectorvia Kimberly Manhard
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $5,498,377
- 14 purchases by 3 insiders
- Sold, last 12 months
- $279,015
- 5 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 28, 2026 | Mark Lappe Director, Officer (Chief Executive Officer) | Open-market purchase | +1,500 | $98.88 | $148,320 |
| Sep 28, 2026 | Mark Lappe Director, Officer (Chief Executive Officer) | Open-market purchase | +3,000 | $101.70 | $305,100 |
| Sep 25, 2026 | Mark Lappe Director, Officer (Chief Executive Officer) | Open-market purchase | +3,324 | $98.87 | $328,644 |
| Sep 25, 2026 | Mark Lappe Director, Officer (Chief Executive Officer) | Open-market purchase | +2,176 | $99.60 | $216,730 |
| Sep 23, 2026 | Jon Faiz Kayyem Director | Open-market purchase | +5,000 | $100.00 | $500,000 |
| Sep 16, 2026 | Jon Faiz Kayyem Director | Open-market purchase | +5,000 | $100.00 | $500,000 |
| Sep 15, 2026 | Kimberly Manhard Director | Open-market sale | −500 | $105.05 | $52,525 |
| Sep 14, 2026 | Kimberly Manhard Director | Open-market sale | −500 | $110.26 | $55,130 |
| Sep 11, 2026 | Kimberly Manhard Director | Open-market sale | −500 | $111.78 | $55,890 |
| Sep 9, 2026 | Kimberly Manhard Director | Open-market sale | −500 | $115.80 | $57,900 |
| Sep 8, 2026 | Douglas Forsyth Director | Open-market purchase | +2,500 | $114.65 | $286,625 |
| Sep 8, 2026 | Mark Lappe Director, Officer (Chief Executive Officer) | Open-market purchase | +5,895 | $99.29 | $585,315 |
| Sep 8, 2026 | Jon Faiz Kayyem Director | Open-market purchase | +5,000 | $113.52 | $567,600 |
| Sep 8, 2026 | Kimberly Manhard Director | Open-market sale | −500 | $115.14 | $57,570 |
| Sep 8, 2026 | Mark Lappe Director, Officer (Chief Executive Officer) | Open-market purchase | +6,605 | $100.64 | $664,727 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Inhibrx Biosciences Inc.
Who is the CEO of Inhibrx Biosciences Inc.?
Mark Lappe has been Inhibrx Biosciences Inc.'s Chief Executive Officer since May 2024.
How many directors are on Inhibrx Biosciences Inc.'s board?
Inhibrx Biosciences Inc.'s board has 5 directors: Douglas Forsyth, Jon Faiz Kayyem, Kimberly Manhard, Kristiina Vuori M.D. and Mark Lappe.
Are Inhibrx Biosciences Inc. insiders buying or selling shares?
Over the last 12 months, Inhibrx Biosciences Inc. insiders bought $5.5 million of shares in 14 purchases and sold $279,015 of shares in 5 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="inhibrx-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.